Doxorubicin vs CMF in the adjuvant treatment of high risk breast cancer

被引：0
|
作者：
Semiglazov, VF [1 ]
Bozhok, AA [1 ]
Ivanova, OA [1 ]
Iranov, VG [1 ]
Golubeva, OM [1 ]
机构：
[1] NN Petrov Oncol Res Inst, St Petersburg, Russia
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷
关键词：
D O I：
10.1016/S0959-8049(98)80154-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
167
引用
下载
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [41] Anthracycline regimens versus CMF in the adjuvant treatment of early breast cancer (EBC): A matter of difference.
    Gennari, A.
    Sormani, M.
    Costantini, M.
    Pronzato, P.
    Rosso, R.
    Bruzzi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 20S - 20S
  • [42] Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha
    Tonini, G
    Nunziata, C
    Prete, SP
    Pepponi, R
    Turriziani, M
    Masci, G
    Graziani, G
    Bonmassar, E
    De Vecchis, L
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 47 (03) : 157 - 166
  • [43] ADJUVANT RANDOMIZED TRIALS OF DOXORUBICIN CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN CYCLOPHOSPHAMIDE TAMOXIFEN AND CMF CHEMOTHERAPY VERSUS TAMOXIFEN IN WOMEN WITH NODE-POSITIVE BREAST-CANCER
    KAUFMANN, M
    JONAT, W
    ABEL, U
    HILFRICH, J
    CAFFIER, H
    KREIENBERG, R
    TRAMS, G
    BRUNNERT, K
    SCHERMANN, J
    KLEINE, W
    MAHLKE, M
    NEISES, M
    STOSIEK, U
    STIGLMAYER, R
    SEEGER, F
    LANGNICKEL, D
    NAGEL, G
    GAMPE, M
    MAASS, H
    KUBLI, F
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 454 - 460
  • [44] Adjuvant treatment for localized breast cancer having a high recurrence risk: and now ... diphosphonates
    Blay, JY
    BULLETIN DU CANCER, 1998, 85 (09) : 741 - 741
  • [45] DOSE-INTENSE ADJUVANT TREATMENT OF HIGH-RISK BREAST-CANCER
    BONADONNA, G
    VALAGUSSA, P
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (07) : 542 - 543
  • [46] Weekly docetaxel vs CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the ELDA trial
    Nuzzo, F.
    Perrone, F.
    Labonia, V.
    Pacilio, C.
    Gravina, A.
    D'Aiuto, G.
    Signoriello, G.
    Landi, G.
    Piccirillo, M. C.
    de Matteis, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 194 - 194
  • [47] Sequential administration of paclitaxel and doxorubicin followed by CMF in women with advanced breast cancer
    Papadimitriou, C
    Dimopoulos, M
    Lazaris, D
    Ampela, C
    Louvrou-Fertaki, A
    Athanassiades, P
    Stamatelopoulos, S
    Keramopoulos, A
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S14 - S14
  • [48] ADJUVANT SYSTEMIC THERAPY IN HIGH-RISK BREAST-CANCER - THE DANISH BREAST-CANCER COOPERATIVE GROUPS TRIALS OF CYCLOPHOSPHAMIDE OR CMF IN PREMENOPAUSAL AND TAMOXIFEN IN POSTMENOPAUSAL PATIENTS
    MOURIDSEN, HT
    ROSE, C
    BRINCKER, H
    THORPE, SM
    RANK, F
    FISCHERMAN, K
    ANDERSEN, KW
    RECENT RESULTS IN CANCER RESEARCH, 1984, 96 : 117 - 128
  • [49] Adjuvant chemotherapy with vincristine, doxorubicin, and cyclophosphamide in the treatment of postenucleation high risk retinoblastoma
    Mustafa, MM
    Jamshed, A
    Khafaga, Y
    Mourad, WA
    Al-Mesfer, S
    Kofide, A
    El-Husseiny, G
    Gray, A
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1999, 21 (05) : 364 - 369
  • [50] CHEMOTHERAPY (CMF)VS COMBINATION OF HORMONAL AND CHEMOTHERAPY (CMF PLUS TAMOXIFEN) IN METASTATIC BREAST-CANCER
    COCCONI, G
    DELISI, V
    BONI, C
    AMADORI, D
    POLETTI, T
    BERTUSI, M
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 302 - 302
12345